Oncoplastic Level 2 Mammoplasty for Large DCIS: 5-Year Results

BACKGROUND

Oncoplastic surgery (OPS) allows wider resections with immediate breast reshaping by mammoplasty. This study reviews our experience with level 2 mammoplasties in patients with histology-proven pure ductal carcinoma in situ (DCIS).

METHOD

From a prospectively maintained database of 392 consecutive oncoplastic level 2 mammoplasties, 68 patients presented with pure DCIS. Involved margin rates and locoregional recurrence rates were calculated, with 76 months (0-166 months) median follow-up.

RESULTS

The mean pathological tumor size was 34 mm (median 26 mm, range 2-106 mm). The mean resection weight was 191 g (median 131 g, range 40-1150 g). Margins were clear in 58 cases (85.3%) and involved in 10 cases (14.7%). Margins were involved in 1 out of 54 (1.9%) cases with tumor size under 50 mm and in 9 out of 14 (64.3%) cases with tumor size higher than 50 mm (p < 0.001). On multivariable analysis, only tumor size > 50 mm [odds ratio (OR) 95.400; p < 0.001] was independently associated with involved margins. Seven patients had mastectomy. The overall breast conservation rate was 89.4%, and 100% for tumors less than 5 cm. There were three local recurrences. The 5-year cumulative incidence for local recurrence was 5.5% (0-11.5%).

CONCLUSIONS

OPS is a safe solution for large DCIS up to 50 mm, with an involved margin rate of only 1.9%, and can thus reduce the mastectomy rate in this group. As margin involvement significantly increases for tumors larger than 5 cm, better preoperative localization and/or wider excisions are necessary in this group.

[Prophylactic hysterectomy in Lynch syndrome: Feasibility and outcomes]

OBJECTIVES

Lynch syndrome (LS) is a hereditary predisposition to cancers, first of all, colo-rectal and endometrial cancers in women. Although recommended, gynecologic screening has never proven its benefit. Prophylactic surgery can be considered once the parental project is completed. There are few data regarding the assessment of prophylactic surgery. The objectives of our study were to evaluate the feasibility and morbidity of prophylactic hysterectomy in patients with Lynch syndrome.

METHODS

This is a descriptive retrospective study of consecutive patients with LS undergoing prophylactic hysterectomy at the Georges-Pompidou European Hospital from 2002 to 2016. We collected demographic characteristics, results of preoperative assessment, intra- and postoperative data, final pathologic result as well as postoperative follow-up data.

RESULTS

Forty patients were included in the study, and seventeen women had a history of colon cancer surgery. All hysterectomies were performed by laparoscopy, with two cases of laparoconversion. Two intraoperative complications occurred: serosal small bowel injuries and superficial bladder injury. Two early postoperative complications occurred (a peritonitis on small bowel perforation and a peritonitis on left ureteral injury) and two late complications (vesico-vaginal fistula and adhesive small bowel obstruction). All operative specimens were benign. With a median follow-up of 28 months [5-52], no patient had peritoneal cancer.

CONCLUSIONS

Our study shows that prophylactic hysterectomy in Lynch syndrome should be done with caution. Per and postoperative complication rates appear to be higher than in general population, probably related to a more frequent history of colorectal cancer. However, total hysterectomy with bilateral salpingo-oophorectomy appears to be an effective strategy for preventing gynecological cancers in women with the Lynch syndrome.

Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?

Background: As a symptom of multiple sclerosis (MS), fatigue is difficult to manage because of its unknown etiology, the lack of efficacy of the drugs tested to date and the absence of consensus about which would be the ideal measure to assess fatigue. Objective: Our aim was to assess the frequency of fatigue in a sample of MS patients and healthy controls (HC) using two fatigue scales, the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS) with physical, cognitive and psychosocial subscales. We also studied the relationship fatigue has with depression, disability and interferon beta. Methods: Three hundred and fifty-four individuals (231 MS patients and 123 HC) were included in this cross-sectional study. Fatigue was assessed using the FSS and MFIS. Depression was measured by the Beck Depression Inventory (BDI), and disability by the Expanded Disability Status Scale (EDSS). A status of fatigue was considered when the FSS≥ 5, of non-fatigue when the FSS≤4, and scores between 4.1 and 4.9 were considered doubtful fatigue cases. Results: Fifty-five percent of MS patients and 13% of HC were fatigued. The global MFIS score positively correlated with the FSS in MS and HC (r=0.68 for MS and r=0.59 for HC, p<0.0001). Nonetheless, the MFIS physical subscale showed the strongest correlation score with the FSS (r=0.75, p<0.0001). In addition, a prediction analysis showed the physical MFIS subscale to be the only independent predictor of FSS score (p<0.0001), suggesting other aspects of fatigue, as cognition and psychosocial functions, may be explored by the FSS to a lesser extent. Depression also correlated with fatigue (r=0.48 for the FSS and r=0.7 for the MFIS, p<0.0001) and, although EDSS correlated with fatigue as well, the scores decreased after correcting for depression. Interferon beta showed no relationship with fatigue. Conclusions: Fatigue is a frequent symptom found in MS patients and clearly related with depression. Each fatigue scale correlates with one another, indicating that they are measuring similar constructs. Nevertheless, spheres of fatigue as cognition and psychosocial functions are probably better measured by the MFIS, although this hypothesis will need to be confirmed with appropriate psychometrical testing.

Significant clinical worsening after natalizumab withdrawal: Predictive factors

We aimed to single out multiple sclerosis (MS) cases with poor outcome after natalizumab withdrawal and to identify predictive variables. We ascertained 47 withdrawals, and compared their pre- and post-natalizumab periods. We objectively defined significant clinical worsening after natalizumab withdrawal as a 2-step increase in Expanded Disability Status Scale (EDSS). We performed regression models. As a group, post-natalizumab annualized relapse rate (ARR) was lower in the post-natalizumab period, and there were no differences in the mean number of gadolinium (Gd)-enhancing lesions between pre- and post-natalizumab magnetic resonance imaging (MRI). Corticosteroid treatment did not change the outcomes. Eight patients (19%) presented significant clinical worsening after natalizumab withdrawal, which was predicted by a higher baseline EDSS and a 1-step EDSS increase while on natalizumab.

A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS

Background:

Steroids improve multiple sclerosis (MS) relapses but therapeutic window and dose, frequency and administration route remain uncertain.

Objective:

The objective of this paper is to compare the clinical and radiologic efficacy, tolerability and safety of intravenous methylprednisolone (ivMP) vs oral methylprednisolone (oMP), at equivalent high doses, for MS relapse.

Methods:

Forty-nine patients with moderate or severe relapse within the previous 15 days were randomized in a double-blind, noninferiority, multicenter trial to receive ivMP or oMP and their matching placebos. Expanded Disability Status Scale (EDSS) scores were determined at baseline and weeks 1, 4 and 12. Brain MRI were assessed at baseline and at weeks 1 and 4. Primary endpoint was a noninferiority assessment of EDSS improvement at four weeks (noninferiority margin of one point), with further key efficacy assessments of number and volume of T1 gadolinium-enhancing (Gd+), and new or enlarged T2 lesions at four weeks’ post-treatment initiation. Secondary outcomes were safety and tolerability.

Results:

The study achieved the main outcome of noninferiority at four weeks for improved EDSS score. No differences were found between ivMP and oMP in the number of Gd+ lesions (0 (0–1) vs 0 (0–0.5), p = 0.630), volume of Gd+ lesions (0 (0–88.0) vs 0 (0–32.9) mm3, p = 0.735), or new or enlarged T2 lesions (0 (0–194) vs 0 (0–123), p = 0.769). MP was well tolerated, and no serious adverse events were reported.

Conclusions:

This study provides confirmatory evidence that oMP is not inferior to ivMP in reducing EDSS, similar in MRI lesions at four weeks for MS relapses and is equally well tolerated and safe.

Trial registration:

clinicaltrials.gov identifier: NCT00753792

Clinical impact of early brain atrophy in clinically isolated syndromes

Background:

The impact of global and tissue-specific brain atrophy on conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS) is not fully gauged.

Objectives:

We aimed to determine the magnitude and clinical relevance of brain volume dynamics in the first year after a CIS.

Methods:

We assessed 176 patients with CIS within 3 months of onset, clinically and by conventional magnetic resonance imaging (MRI) scans, at baseline and 1 year after clinical onset. We determined the percentage of brain volume change (PBVC) and the brain parenchymal (BPF), grey matter (GMF) and white matter (WMF) fractions.

Results:

The mean follow-up time was 53 months (SD = 16.8): 76 patients (43%) experienced a second attack, 32 (18%) fulfilled MRI-only 2005 McDonald criteria and 68 (39%) remained as CIS. Statistically significant decreases in the volume measures tested were observed in patients with a second attack, for BPF and PBVC; in both MS groups for GMF; whereas in all groups, the WMF was unchanged. Patients with a second attack had larger PBVC decreases (− 0.65% versus + 0.059%; p < 0.001). PBVC decreases below − 0.817% independently predicted shorter times to a second attack.

Conclusions:

Global brain and grey matter volume loss occurred within the first year after a CIS; brain volume loss predicted conversion to MS.

Oncoplastic surgery for breast cancer based on tumour location and a quadrant-per-quadrant atlas

BACKGROUND

The majority of published techniques for oncoplastic surgery rely on an inverted-T mammoplasty, independent of tumour location. These techniques, although useful, cannot be adapted to all situations. A quadrant-per-quadrant atlas of mammoplasty techniques for large breast cancers was developed in order to offer breast surgeons a technique dependent on tumour location, which reduces the risk of postoperative complications and delay to adjuvant therapy.

METHODS

From 2005 to 2010, a series of eligible women with breast cancer were treated by quadrant-specific oncoplastic techniques. All complications and any delay to adjuvant treatment were recorded prospectively, along with local and distant cancer recurrences. Cosmetic outcome was evaluated using a five-point scale.

RESULTS

A total of 175 patients were analysed. The median tumour size, after histological examination, was 25 (range 4-90) mm. Twenty-three patients (13.1 per cent) had involved margins. Seventeen of these patients were treated by mastectomy and three had a re-excision. Complications occurred in 13 patients (7.4 per cent), which led to a delay to adjuvant treatment in three (1.7 per cent). After a median follow-up of 49 (range 23-96) months, three patients had developed a local recurrence. The mean score after cosmetic evaluation was 4.6 of 5.

CONCLUSION

A quadrant-per-quadrant approach to oncoplastic techniques for breast cancer was developed that tailors the mammoplasty for each tumour location. This panel of techniques should be a useful guide for breast surgeons, and extends the possibilities for breast conservation for large or poorly limited cancers, with a low complication rate and good cosmetic results.

[Autologous fat grafting to the postmastectomy irradiated chest wall prior to breast implant reconstruction: a series of 68 patients]

INTRODUCTION

After radiotherapy, breast reconstruction with an implant carries a high risk of failure and complication. Clinical and experimental studies have demonstrated that grafting adipose tissue (lipofilling) in an irradiated area enhances skin trophicity. Thus, we have started performing preliminary fat grafting to the irradiated chest wall prior to implant reconstruction in order to limit complications and failure risk.

PATIENTS AND METHODS

Patients were included in this study from 2007 to 2011. All patients had had mastectomy and irradiation for breast cancer. They all had one or more sessions of lipofilling prior to breast implant reconstruction. These patients were prospectively followed up in order to collect the following data: postoperative complications; cosmetic result; local breast cancer recurrences.

RESULTS

Sixty-eight patients were included. The mean number of fat grafting sessions was 2.3 (range 1-6). An average volume of 115mL (70-275) was injected each time. The mean volume of breast implants was 300mL (185-400). The mean follow-up was 23months (450). No breast cancer local recurrence was diagnosed during follow-up. Implant explantation was performed in one case (1.47%) The mean cosmetic result was 4.5/5.

CONCLUSION

Fat grafting to the irradiated chest wall prior to implant placement might be an alternative to flap reconstruction for patients who are not suitable or who refuse this option.

Complications of lymphadenectomy for gynecologic cancer

INTRODUCTION

Symptomatic postoperative lymphocysts (SPOLs) and lower-limb lymphedema (LLL) are probably underestimated complications of lymphadenectomy for gynecologic malignancies. Here, our objective was to evaluate the incidence and risk factors of SPOLs and LLL after pelvic and/or aortocaval lymphadenectomy for gynecologic malignancies.

METHODS

Single-center retrospective study of consecutive patients who underwent pelvic and/or aortocaval lymphadenectomy for ovarian cancer, endometrial cancer, or cervical cancer between January 2007 and November 2008. The incidences of SPOL and LLL were computed with their 95% confidence intervals (95%CIs). Multivariate logistic regression was performed to identify independent risk factors for SPOL and LLL.

RESULTS

We identified 88 patients including 36 with ovarian cancer, 35 with endometrial cancer, and 17 with cervical cancer. The overall incidence of SPOL was 34.5% (95%CI, 25-45) and that of LLL was 11.4% (95% confidence interval [95%CI], 5-18). Endometrial cancer was independently associated with a lower risk of SPOL (adjusted odds ratio [aOR], 0.09; 95%CI, 0.02-0.44) and one or more positive pelvic nodes with a higher risk of SPOL (aOR, 4.4; 95%CI, 1.2-16.3). Multivariate logistic regression failed to identify factors significantly associated with LLL.

CONCLUSION

Complications of lymphadenectomy for gynecologic malignancies are common. This finding supports a more restrictive use of lymphadenectomy or the use of less invasive techniques such as sentinel node biopsy.

Hirano body-rich subtypes of Creutzfeldt-Jakob disease

BACKGROUND

In definite Creutzfeldt-Jakob disease (CJD), morphological and immunohistochemical patterns are useful to identify molecular subtypes. Severe cerebellar pathology and hippocampal involvement helps to identify VV subtypes. The rare VV1 variant (<1%), more frequent in young individuals, is additionally characterized by the presence of ballooned neurones in affected areas. In 1985, Cartier et al. described a family cluster of three individuals with an ataxic CJD form, showing, in addition to severe cerebellar and hippocampal involvement, the presence of frequent Hirano bodies (HB) in CA1 pyramidal neurones. HB are frequently found in aged individuals with Alzheimer pathology although they are not a specific finding.

AIMS AND METHODS

In this study, we evaluated the presence of HB in hippocampi of 54 genetically and molecularly characterized CJD cases, aiming to elucidate whether additional morphological features could be helpful to point to molecular subtypes.

RESULTS

We identified nine cases (four VV1, one out of three MV2K, three out of six MV2K+2C and one MV carrying a 96-base pair insertion) with abundant, partly bizarre and clustered HB in CA1 sector, not observed in other subtypes. The presence of HB was independent of hippocampal involvement by the disease itself.

CONCLUSIONS

Clusters of abundant HB might be found in rare CJD subtypes such as VV1, MV2K/MV2K+2C and some genetic cases. In addition to histopathological and PrP immunohistochemical deposition patterns, their presence might be a useful additional morphologic feature that could point to the molecular subtype, especially when genetic and/or Western blot analyses are not available.

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

BACKGROUND

  Therapy for multiple sclerosis (MS) has a partial efficacy, and a significant proportion of treated patients will develop a suboptimal response with first-line disease-modifying drugs (DMD). Therapy switch in patients with MS can be a strategy after a treatment failure. We studied the change in clinical activity after switching of first-line DMD because of a treatment failure.

METHODS

  Relapsing-remitting multiple sclerosis (RRMS) patients treated with interferon-beta (IFNB) or glatiramer acetate (GA) were divided into (i) patients without change in DMD, (ii) patients with a change in DMD because of a poor response, and (iii) those with a change in DMD without relation with response. Annualized relapse rate (ARR) and relapse-free proportions were analyzed.

RESULTS

  We identified 923 patients with RRMS. Of the 180 who experienced a change because of suboptimal response, 90 switched to another first-line DMT, 38 to mitoxantrone, and 52 to natalizumab. Median ARR in the pre-DMD period on first DMD and second DMD was the following: 1, 1, and 0 for switchers from IFNB to another IFNB (P = 0.0001); 0.67, 1, and 0 for switchers from GA to IFNB (P = 0.01); 1, 1, and 0 for switchers from an IFNB to GA (P = 0.02); 1.1, 1.5, 0.2 for switchers from IFNB or GA to mitoxantrone (P = 0.0001); 0.9, 1, 0 for switchers from IFNB or GA to natalizumab (P = 0.0001).

CONCLUSIONS

  In patients with RRMS who have a poor response, switch to another DMD may reduce the clinical activity of the disease.

[Sentinel lymph node biopsy and axillary reverse mapping: a tailoring axillary staging in breast cancer]

The status of the axillary lymph nodes is one of the most important prognostic factors in women with early stage breast cancer. Histologic examination of removed lymph nodes is the most accurate method for assessing spread of disease to these nodes. Axillary lymph node dissection (ALND) remains the standard approach for women who have clinically palpable axillary nodes. The benefits of ALND include its impact on disease control (axillary recurrence and survival), its prognostic value, and its role in treatment selection. However, the anatomic disruption caused by ALND may result in lymphedema, nerve injury, and shoulder dysfunction, which compromise functionality and quality of life. For patients who have clinically negative axillary lymph nodes, sentinel lymph node (SLN) biopsy offers a less morbid method to determine if there are positive nodes, in which case axillary node dissection would be necessary. Patients who are SLN-positive should undergo complete ALND. Axillary reverse mapping (ARM) is a recent improvement of ALND which, like the biopsy of the GS, would reduce morbidity.

Adipose-tissue grafting to the post-mastectomy irradiated chest wall: preparing the ground for implant reconstruction

INTRODUCTION

Breast implant reconstruction after radiotherapy carries a high risk of failure and complication. Nevertheless, it may be the only alternative for patients who are not suitable for autologous reconstruction or who refuse this option. As clinical and experimental studies have demonstrated that grafting adipose tissue (lipofilling) in an irradiated area improves the quality of the skin, we made the assumption that preliminary fat grafting of the chest wall might reduce the complication and failure rates of implant reconstruction by improving the implant coverage.

PATIENTS AND METHODS

From 2007 to 2009, 28 patients had fat transfer to the chest wall, prior to implant reconstruction. All patients had had mastectomy and irradiation for breast cancer. Lipofilling was initiated 6 months after the end of radiotherapy. The mean number of fat-grafting sessions was 2 (range 1-3). An average volume of 115 cc (70-275 cc) was injected each time. Once the chest wall's skin seemed to have gained enough thickness, implant reconstruction was performed.

RESULTS

The mean follow-up period was 17 months. Three minor complications occurred. Implant explantation was performed in one case for exposition. The cosmetic results were good and very good in >80% of the cases.

CONCLUSION

This study points out the benefits of fat grafting to the irradiated chest wall prior to implant placement and demonstrates that lipofilling prepares the ground to implant breast reconstruction. This approach could be considered as an alternative to flap reconstruction for selected patients.

An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis

AIM

To analyse the safety and effectiveness of natalizumab in the treatment of multiple sclerosis in a real clinical practice setting and according to the approved indications.

PATIENTS AND METHODS

All patients with multiple sclerosis treated with natalizumab in our centre were evaluated. The clinical and radiological disease activity during the first year of treatment was analyzed in patients who received at least 12 doses of the drug. The data regarding moderate and severe adverse events in the entire study sample was also evaluated.

RESULTS

A total of 112 patients were included in the study, of which 110 had been previously treated with other drugs and 76 had received at least 12 doses of natalizumab. In this group, the annualized relapse rate was reduced by 89% compared to the preceding year and 80% of patients were free from relapses after one year of treatment. Nine percent of patients exhibited 3-month confirmed disability progression. At month 12, the mean number of gadolinium-enhancing lesions on brain MRI was decreased by 99% compared to the pre-treatment MRI. During the first year of treatment, 76% of patients remained free from clinical activity and 33% remained free from both clinical and radiological disease activity. Twenty-nine percent of patients had at least one moderate or severe adverse event, which led to treatment discontinuation in 6%. Four percent of patients experienced immediate hypersensitivity reactions.

CONCLUSION

This study suggests that natalizumab is effective in reducing disease activity in patients with relapsing multiple sclerosis and inadequate response to other therapies, with a favorable risk-benefit ratio.

Brainstem lesions in clinically isolated syndromes

BACKGROUND

Number of baseline lesions has been shown to predict future attacks and disability in clinically isolated syndromes (CIS).

OBJECTIVE

To investigate the role of baseline infratentorial lesions in long-term prognosis.

METHODS

Subjects were included in a prospective cohort of patients with CIS. Patients underwent brain MRI within 3 months after CIS onset. Number and location of lesions at baseline were prospectively studied. Retrospective scan analysis was conducted to specifically look at number and location of infratentorial lesions. We analyzed the time to a second attack and to reach EDSS 3.0.

RESULTS

We included 246 patients with CIS followed for a median of 7.7 years. Patients with infratentorial lesions had both a higher risk of conversion (71.4% vs 29.6%; hazard ratio [HR] 3.3; 95% confidence interval [CI] 2.2-4.8; p < 0.001) and of developing disability (32.5% vs 12.4%; HR 2.4; 95% CI 1.3-4.3; p = 0.003). Presence of at least one cerebellar lesion was associated with an increased risk of conversion (HR 2.4; 95% CI 1.3-4.5; p = 0.007). Presence of at least one brainstem lesion increased both the risk of conversion (HR 2.9; 95% CI 1.7-5.0; p < 0.001) and disability (HR 2.5; 95% CI 1.1-5.4; p = 0.026). Broken down into number of lesions, the presence of infratentorial lesions increased both the risk of conversion (83% vs 61%) (HR 22.3; 95% CI 9.7-51.1; p < 0.001) and of reaching EDSS 3.0 (40% vs 19%) (HR 3.2; 95% CI 1.3-7.4; p = 0.008) only in patients with 9 or more lesions.

CONCLUSIONS

Presence of infratentorial lesions increases the risk for disability. Brainstem rather than cerebellar lesions may be responsible for poor prognosis.

Abstract P4-10-09: An Oncoplastic Surgical Planning Tool Based on Tumor Location Improves Breast Conservation Outcomes

OBJECTIVE

Oncoplastic Surgery is an evolving field in breast cancer surgery. Considerable variations in oncoplastic surgery (OPS) for breast conservation (BCS) have developed as the interest and utilization by both breast surgeons and plastic surgery teams continues to increase. Our goal is to assess the effectiveness of an oncoplastic surgical planning tool for BCS. The tool is a surgical atlas and guide that matches oncoplastic procedure recommendations for a specific tumor location.

BACKGROUND

Oncoplastic surgery for the treatment of breast cancer has been validated compared to standard BCS in terms of rate of re-excision, preservation of the natural breast shape, complications and 5-year local recurrence rates. Oncoplastic surgery incorporates plastic surgery techniques for the purpose of breast conservation. A bi-level OPS classification system and guide for patient selection was created to improve both patient outcomes and enable all breast surgeons to choose a safe and effective oncoplastic approach.

METHODS

This is a single institution prospective study of patients with breast cancer that had an oncoplastic level II procedure for breast conservation between 2005 and 2009 at the Paris Breast Center. The corresponding level II OPS technique was chosen for each patient based on the principals of patient selection and tumor location described in the atlas. A set of objective outcomes as well as an aesthetic evaluation was recorded based on tumor location and choice of procedure.

Results

A total of 151 patients met the criteria for performing a level II OPS for breast conservation based on the selection process outlined in the oncoplastic Atlas. The overall adherence rate for selection of procedure based on tumor location was 90%. The reexcision rate was 4% with greater then 80% of patients achieving a margin width exceeding .5cm and an average specimen weight of 144 grams. The conversion rate to mastectomy approached 12%. We found a good to excellent aesthetic outcome in 95% of evaluated patients. The rate of deformity in this level II OPS series was 0%. The early complication rate was 11% resulting in a delay of treatment for adjuvant therapy in less then 2% of patients.

Tumor Location and OPS Level II Procedure

Complications and Delay in Treatment

CONCLUSIONS

Adherence to the oncoplastic surgical guide resulted in an acceptable reexcision rate with the elimination of the risk of deformity for patients undergoing large volume resections for breast conservation. This initial assessment validates the efficacy of the atlas and provide surgeons with a reliable system to correctly choose the most appropriate oncoplastic procedure based on tumor location and avoids the complications associated with a one technique fits all approach for OPS.

[Current indications of lymphadenectomy in endometrial cancer]

Endometrial cancer is a tumor associated with a good prognosis as it is often diagnosed at an early stage. Up to 20 % of patients with stage I disease have a nodal involvement. Knowledge of nodal status provides important prognostic information. As preoperative assessment yields a poor value, prognostic lymphadenectomy appears to be indicated. However, therapeutic benefit of pelvic and para-aortic lymphadenectomy remains controversial. Recent randomized trials did not find any impact on survival for patients with low risk of nodal involvement. Thus, lymphadenectomy should no more be systematically performed in this low risk group. Nevertheless, pelvic and para-aortic lymphadenectomy seems to have a benefit in the high risk group, as isolated involved para-aortic nodes have been described.

New anatomical classification of the axilla with implications for sentinel node biopsy

Background

The exact anatomical location of the sentinel lymph node (SLN) in the axilla has not ascertained clinically, but could be useful both for teaching purposes and to reduce the morbidity of SLN biopsy. The aim of the study was to determine the position of the SLN in the axilla and to demonstrate that this location is not random.

Methods

A consecutive series of 242 patients with stage I breast cancer (T1/T2 N0) or ductal carcinoma in situ who underwent SLN localization by peritumoral injection were included in a prospective study to map the location of the SLN in the axilla. A new anatomical classification of the lower part of the axilla based on the intersection of two anatomical landmarks, the lateral thoracic vein (LTV) and the second intercostobrachial nerve (ICBN), is described. These two constant elements form the basis of four axillary zones (A, B, C and D).

Results

In 98·2 per cent of patients the axillary SLN was located medially, alongside the LTV, either below the second ICBN (zone A, 86·8 per cent) or above it (zone B, 11·5 per cent). In only four patients (1·8 per cent) was the SLN located laterally in the axilla.

Conclusion

Regardless of the site of the tumour in the breast, 98·2 per cent of SLNs were found in the medial part of the axilla, alongside the LTV. This information should help to avoid unnecessary lateral dissections.

[Multiple sclerosis epidemiological situation update: pertinence and set-up of a population based registry of new cases in Catalonia]

INTRODUCTION

The first epidemiological studies on multiple sclerosis (MS) around the world pictured a north to south latitudinal gradient that led to the first genetic and environmental pathogenic hypothesis. MS incidence seems to be increasing during the past 20 years based on recent data from prospective studies performed in Europe, America and Asia. This phenomenon could be explained by a better case ascertainment as well as a change in causal factors. The few prospective studies in our area together with the increase in the disease in other regions, justifies an epidemiological MS project in order to describe the incidence and temporal trends of MS.

DEVELOPMENT

A prospective multicenter MS registry has been established according to the actual requirements of an epidemiological surveillance system. Case definition is based on the fulfillment of the McDonald diagnostic criteria. The registry setting is the geographical area of Cataluna (northeastern Spain), using a wide network of hospitals specialized in MS management.

CONCLUSION

Recent epidemiological studies have described an increase in MS incidence. In order to contrast this finding in our area, we consider appropriate to set up a population based registry.

Prospective Evaluation of Pre and Postoperative Lymphoscintigraphy in Axillary Reverse Mapping (ARM) for Breast Cancer Patients

BackgroundThe sentinel lymph node (SLN) procedure, has been used successfully to detect lymphatic involvement. The expected reduction in morbidity and improvement in the quality of life of patients remains uncertain. In spite of this minimal invasive technique, 40 to 50 % of axilla are explored by classic axillary dissection. The aim of axillary reverse mapping (ARM) is to preserve the main lymphatic chain in relation to lymphatic arm drainage during an axillary dissection, reducing the rate of lymphedema.ObjectivesThe objective of this study is to describe a prospective comparison of pre and post axillary dissection (AD) lymphoscintigraphy, in 15 consecutive breast cancer patients.MethodsIsotope InjectionThe morning of surgery, all patients underwent isotope injection in the ipsilateral hand. Each patients received a single injection of 60 MBq (vol 0.2 ml) into the first interdigital space. The preoperative lymphoscintigraphy was performed 45 min after injection, in surgical position. An average of 2 nodes were visible in the axilla. The postoperative lymphoscintigraphy was planned before starting adjuvant treatment.Surgical TechniqueAfter having performed the lumpectomy or the mastectomy, the surgeon began the AD. The first important step was the identification of the second intercostals brachial nerve. While reserving the nerve, the dissection was carried out from medial to lateral, below the nerve. The gamma probe was then used in order to identify the first radioactive node draining the upper limb. This node was localized in the lateral pillar of the axilla. The ARM nodes were carefully preserved during the dissection with retractors placed over them to protect from inadvertent damage. After completion of AD, the axillary content was examined ex-vivo to identify at least ten nodes within the surgical specimen.ResultsThe mean age is 62.4 years (range 40-81). For all 15 patients, the mean number of axillary nodes removed by means of AD was 10.7 (range 7–14). Of all patients, 3 (87%) had metastatic involvement in the AD with an average of 1.3 (range 1– 2) nodes involved.A lymphoscintigraphic mapping concordance between pre and post, was found in 13 out 15 patients (87%).ConclusionsIsotopic ARM allows identification of radioactive nodes in the axilla in 91% of cases.The very good correlation between pre and postoperative mapping suggests a persistence of the normal LAD, and lets hope for a risk reduction of lymphodema after AD.A longterm follow up is needed to confirm these very promising preliminary results.

Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1025.

Intraoperative Determination of Axillary Node Metastasis: Meta-Analysis of Diagnostic Accuracy Assessment Studies for Frozen Section, Imprint Cytology and Molecular Assays

Background: Sentinel lymph node status is highly predictive of overall axillary lymph node involvement. Intraoperative assessment potentially enables completion of axillary dissection at the same setting. The most commonly used methods are frozen section histology and imprint cytology. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays have been recently developed.Objectives: To obtain summary estimates of the diagnostic accuracy of intraoperative tests for the detection of metastases in lymph nodes of patients with breast cancer.Selection criteria: Cross-sectional studies assessing the diagnostic accuracy of at least one index test for the detection of metastases in lymph nodes of patients with breast cancer were selected. Index tests included frozen section, touch imprint cytology or RT-PCR with the One-Step Nucleic Acid Amplification (OSNA) technique (Sysmex) or GeneSearch™ Breast Lymph Node (BLN) Assay (Veridex, LCC). The reference standard was permanent section H&E analysis.Search strategy: We searched MEDLINE and EMBASE up to April 2009 with both controlled vocabulary and freetext words corresponding to 'breast cancer' and 'lymph node' and 'intraoperative test'. We also searched SABCS and ASCO annual meeting proceedings from 2006 to 2008 as well as Sysmex, Veridex and FDA websites. We checked the reference lists of selected studies and review articles for additional studies.Data collection and analysis: Two review authors independently applied the selection criteria to identify references and reached consensus at each step. Both independently assessed quality according to the QUADAS checklist and extracted data from selected studies. Meta-analysis was performed using a bivariate mixed-effect model. Per-patient and per-node combined sensitivity and specificity were calculated.Results: Among 560 screened references from MEDLINE or EMBASE, 100 references were selected (43 pending decisions because of availability or translation issues). We identified 29 additional articles or abstracts from other sources. Of these, 3 independent studies (667 nodes) assessed GeneSearch™ BLN Assay accuracy on a per-node basis: combined sensitivity was 0.86, 95%CI:0.63-0.96 and combined specificity 0.94, 95%CI:0.92-0.96. Six independent studies (2091 nodes) assessed OSNA accuracy on a per-node basis: combined sensitivity was 0.93, 95%CI:0.86-0.96 and combined specificity 0.95, 95%CI:0.92-0.97. In 5 studies reporting data corrected for sampling bias, sensitivity was 0.94, 95%CI:0.86-0.97 and specificity 0.96, 95%CI:0.94-0.97.Conclusion: Our preliminary results indicate that RT-PCR yields high per-node sensitivity and specificity. OSNA tends to show a nonsignificantly higher accuracy than GeneSearch™ BLN Assay. Updated results, including frozen section, imprint cytology and subgroup analyses, will be presented at the congress.

Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1005.

Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?

The role of multimodal evoked potentials (MMEPs) in establishing multiple sclerosis (MS) diagnosis and prognosis has diminished nowadays. The objective of this article is to evaluate whether MMEPs add information to MRI in identifying patients with higher risk of relapse or development of disability after a clinically isolated syndrome (CIS). Patients who underwent visual, somato-sensory and brainstem auditory evoked potentials (EPs) were identified from a cohort of consecutive CIS. Patients also underwent brain MRI within 3 months of first attack. We analysed time to second attack and to Expanded Disability Status Scale (EDSS) score of 3.0 according to number of Barkhof criteria and number of abnormal MMEPs. A complete study was performed in 245 patients who were followed for a mean of 76.4 months (interquartile range: 61 to 96). Seventy-one patients (29%) had the three EPs normal, 115 patients (47%) had one abnormal EP; 40 patients (16%) had two; and 19 patients (8%) had three abnormal EPs. Baseline MRI determined the risk for converting to clinically definite MS and correlated with disability according to previous studies. EPs individually did not modify the risk of conversion or disability. However, the presence of three abnormal EPs increased the risk of reaching moderate disability (hazard ratio 7.0; 1.4—34.9) independently of baseline MRI. In conclusion, in the presence of three abnormal EPs could help identify CIS patients with a higher risk of developing disability, independently of MRI findings. However, the utility of MMEPs is limited by the low percentage of CIS patients having the three abnormal at baseline.

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

Inflammation and neurodegeneration may have differential impacts on disease evolution in the different forms of multiple sclerosis. However, a beneficial effect of immunomodulatory drugs should not be ruled out in primary progressive multiple sclerosis. Our aim is to investigate the safety and efficacy of interferon beta-1b in primary progressive multiple sclerosis. We conducted a double-blind, stratified, randomized, parallel group, phase II pilot study where patients with primary progressive multiple sclerosis or ‘transitional’ forms of multiple sclerosis received interferon beta-1b at doses of 8 MIU or placebo for 24 months. The main objective of the study was to investigate the safety and tolerability of interferon beta-1b. The primary efficacy variable was the time to neurological deterioration (Expanded Disability Status Scale) confirmed at 3 months. Seventy-three patients were included and three dropped out the study. More patients in the treatment arm had at least one related adverse event (94.4% versus 45.9%; p < 0.001); no other significant differences in safety endpoints were observed. Time to neurological deterioration was not different between trial arms (log-rank test, p = 0.3135). Statistically significant differences favoring treatment were observed for the Multiple Sclerosis Functional Composite score at several timepoints, T1 and T2 lesion volume changes at 12 and 24 months, mean number of active lesions and proportion of patients with active lesions at 24 months. We conclude that interferon beta-1b is safe and well tolerated in patients with primary progressive multiple sclerosis and transitional multiple sclerosis. Positive effects of interferon beta on secondary clinical and magnetic resonance imaging outcomes were observed, but a beneficial effect on Expanded Disability Status Scale progression was not demonstrated.

Measures in the first year of therapy predict the response to interferon beta in MS

BACKGROUND AND OBJECTIVE

Several criteria for treatment response to interferon beta (IFNbeta) have been proposed, although there is no consensus among different investigators. Hence, the aim of this study was to investigate magnetic resonance imaging (MRI) and clinical predictors of response during the first 12 months of therapy.

METHODS

This is a prospective and longitudinal study of relapsing-remitting multiple sclerosis (RRMS) patients treated with IFNbeta. Patients were classified based on the presence of new lesions on MRI, relapses, confirmed disability increase, or combinations of all these variables after 1 year of therapy. Regression analysis was performed in order to identify variables of response after a follow-up of 3 years.

RESULTS

We included 222 RRMS patients. The logistic model demonstrated that only the combination of new active lesions on MRI with the presence of relapses (OR 4.4; 95% CI 1.6-12.5) or disability progression (Odds Ratio (OR) 7.1; 95% Confidence Interval (CI) 1.6-33.9), or both (OR 6.5; 95% CI 1.9-23.4) achieved significant values to identify those patients with a poor outcome.

CONCLUSIONS

In RRMS patients treated with IFNbeta, the combination of measures of disease activity and the presence of new active lesions on MRI may have a prognostic value for identifying patients with disease activity in the second and third year of therapy.

Intra-operative sentinel lymph node metastasis detection by “one-step nucleic acid amplification (OSNA)”: results of the french multicentric study

Abstract #1004

Background: Sentinel node (SLN) biopsy is widely used as a staging procedure in early breast cancer. usual procedures for intra-operative assessment have a low sensitivity and lead to reoperations for axillary dissection when the SLN is metastatic. The semi-automated OSNA test is based on a short sample preparation step and subsequent rapid amplification of CK19 mRNA. Results are available within 30 - 40 minutes. The OSNA method was developed to accurately detect metastases (≥ 0.2mm) in an intra-operative setting. The objective of this study was to evaluate diagnostic performance of OSNA in comparison to intensive histological examination.&#x2028; Methods: A total of 509 fresh SLN (234 patients) were cut into four slices. Two alternate slices were analysed by OSNA, the remaining ones were cut at 200µm intervals. On each level, Haematoxylin & Eosin and immunohistochemical staining (CK19 and AE1/AE3) were performed. In case of discordant results, the lysates of samples were subjected to QRT-PCR and Western Blot (Discordant Case Investigation, DCI) in order to detect whether the discordances were caused by tissue allocation bias (TAB): localisation of tumour deposits in only one slice due to the study design.&#x2028; Results: results were concordant for 202/234 patients (33 positive and 169 negative). 17/32 discordant cases were due to TAB. 2 cases were ininterpretable due to procedure errors. For remaining discordant cases, 2 were histology + / OSNA - and 11 were histology - / OSNA + (8 of them had CK 19 expression levels close to the cutoff). The sensitivity was 94.30% and specificity 93.90%. The overall concordance rate was 93.96%.&#x2028; Conclusion: OSNA is a rapid and accurate tool for intra-operative assessment of SLN and could reduce the reoperation rate for secondary axillary dissection when the SLN is metastatic.

Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1004.

Impact of fat grafting the chest wall prior to implant reconstruction in high risk patients

Abstract #4143

Background: Breast reconstruction with implants in patients that have either received chest wall irradiation or have relatively thin mastectomy skin flaps carry a higher risk of short and long term failure compared to patients undergoing autologous reconstructions. Patients treated with chest wall irradiation are at highest risk of complications, ranging from 30.2% to 37% and 9.2% to 68% respectively. Improvement in the complication rates in patients identified at higher risk can be achieved through either sequential or singular fat grafts to the subcutaneous tissue of the chest wall prior to implant reconstruction.&#x2028; Material and Methods: Patients undergoing implant reconstruction identified through either a history of chest wall irradiation or thin tissue coverage of the chest on physical exam were considered candidates for pre-reconstruction fat grafting. After grafting and completion of implant reconstruction the patients were followed prospectively for a mean of 6 months to evaluate for both early and late complication rates as well as the aesthetic outcome. The lipo-aspirate used in grafting was obtained from either the abdomen or inner thigh areas. The components of the aspirate were then separated by centrifugation at a rate of 3000rpm for 3 minuets. Isolated fat component was injected into both the subcutaneous tissue and retro-muscular plane.&#x2028; Results: There were 9 patients that had pre-operative lipofilling prior to implant reconstruction. Of these patients 3 underwent radiation to the skin overlying the chest wall and the remaining 6 had poor chest wall tissue coverage. Follow-up length ranged from 3 – 12 months. During the course of treatment no patients had either short (&lt;2 months) or long term (&gt;2 months) complications that involved: infection, seroma, hematoma, and skin flap necrosis. Revision surgery was performed in 1 patient 2 months after reconstruction due to implant malrotation. Both patient and surgeon satisfaction with the overall breast shape and appearance was good to very good. None of the patients had a local recurrence of their cancer during the follow-up interval nor complications related to the lipofilling procedures.&#x2028; Conclusion: Fat grafting prior to delayed implant reconstruction can decrease complication rates and improve cosmetic outcome in high risk patients. The improvement seen with fat grafting may be attributed to increased thickness and improved vascularity of the overlying subcutaneous tissue and skin. The real and theoretical complications of fat grafting such as the oncogenic potential of the lipo-aspirate in patients with a history of breast cancer needs further consideration.&#x2028; 1 Krueger EA, Wilkins EG, Pierce LJ, et al. Complications and patient satisfaction following expander/implant breast reconstruction with and without radiotherapy. Int J Radiation Oncology Biol Phys 2001;49(3):713-721.&#x2028; 2 Clough KB, O'Donoghue JM, Fitoussi AD, Nos C, Falcou MC. Prospective evaluation of late cosmetic results following breast reconstruction: I. implant reconstruction. Plast Reconstr Surg. 2001;107(7):1702-9.

Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4143.

A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis

PURPOSE

Predictive factors of non-sentinel lymph node (NSN) involvement at axillary lymph node dissection (ALND) have been studied in the case of sentinel node (SN) involvement, with validation of a nomogram. This nomogram is not accurate for SN micrometastasis. The purpose of our study was to determine a nomogram for predicting the likelihood of NSN involvement in breast cancer patients with a SN micrometastasis.

METHODS

We collated 909 observations of SN micrometastases with additional ALND. Characteristics of the patients, tumours and SN were analysed.

RESULTS

Involvement of SN was diagnosed 490 times (53.9%) with standard staining (HES) and 419 times solely on immunohistochemical analysis (IHC) (46.1%). NSN invasion was observed in 114 patients (12.5%), whereas 62.3% (71) had only one NSN involved and 37.7% (43) two or more NSN involved. In multivariate analysis, significant predictive factors were: tumour size (pT stage < or = 10 mm or >11 and < or = 20 or >20 mm [odds ratio (OR) 2.1 and 3.43], micrometastases detected by HES or IHC [OR 1.64], presence or absence of lymphovascular invasion (LVI) [OR 1.76], tumour histological type mixed or not [OR 2.64]. The rate and probability of NSN involvement with the model are given for 24 groups, with a representation by a nomogram.

CONCLUSION

One group, corresponding to 10.1% of the patients, was associated with a risk of NSN involvement of less than 5%, and five groups, corresponding to 29.8% of the patients, were associated with a risk < or = 10%. Omission of ALND could be proposed with minimal risk for a low probability of NSN involvement.

[Acute disseminated encephalomyelitis: study of factors involved in a possible development towards multiple sclerosis]

Acute disseminated encephalomyelitis (ADEM) is an uncommon disease characterized by inflammation and demyelination of the central nervous system (CNS). It typically occurs after a viral infection or vaccination and is more frequent in children. Its immediate and longterm prognosis is expected to be good (20% of cases with sequelae). Although ADEM is typically monophasic, occasional relapses may occur. Differential diagnosis, mostly in the early phases, is established with multiple sclerosis (MS), a chronic inflammatory demyelinating disease of the CNS that may have worse prognosis. Traditionally it has been believed that 10% of ADEM patients develop MS. However, this percentage could be higher according to several recently published clinical series. Some clinical and paraclinical patterns are considered to confer risk of developing MS when present in ADEM patients. Our study has aimed to: a) describe a series of 29 patients (22 children and 9 adults) admitted in our hospital and diagnosed of ADEM between 1990 and 2005; b) study those patients considered to have risk patterns of developing MS, and c) compare the child and adult populations of our series. After a median 55 month follow-up, 6 children (27%) and no adults developed MS. In our series, risk patterns for developing MS predicted conversion to MS more accurately in children than in adults. Eight patients (6 children and 2 adults) had sequelae, cognitive in 6 of them. Our work supports that also observed in recent publications: that both conversion to MS or presence of sequelae after an episode of ADEM are more frequent than traditionally considered.

Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients

OBJECTIVE

Our objective in this study is to evaluate whether brain magnetic resonance imaging (MRI) performed at interferon-beta (IFN-beta) onset and after 12 months allow us to identify relapsing-remitting multiple sclerosis (RRMS) patients with a disability increase in the first 2 years of therapy.

METHODS

This is a prospective and longitudinal study of patients with RRMS treated with IFN-beta. All patients included underwent brain MRI before the onset of therapy with IFN-beta and 12 months after. MRI measures (T2, unenhanced T1-weighted and gadolinium-enhancing T1-weighted brain lesion load, brain parenchymal fraction) were undertaken at baseline and after 12 months. The number of active lesions (new or enlarging T2 plus gadolinium-enhancing brain lesions) was also assessed on the 12 months MRI scan. Expanded Disability Status Scale (EDSS) was scored every 3 months. We defined an increase in disability as an increase of at least 1 EDSS point confirmed and sustained during the first 2 years of therapy with IFN-beta. Regression analysis was performed in order to identify MRI variables of response.

RESULTS

We included 152 patients who were followed-up for at least 2 years. After 2 years of therapy, 24 patients (16%) had an increase in disability. The logistic regression model showed that active lesions in the scan performed at 12 months were the most important factor related with the increase of disability after 2 years of therapy (odds ratio 8.3, 95% confidence interval 3.1-21.9; p < 0.0001).

CONCLUSIONS

In RRMS patients treated with IFN-beta the MRI changes occurring during the first year may have a prognostic value for identifying patients with a confirmed increase of disability after 2 years of therapy.

Very early scans for demonstrating dissemination in time in multiple sclerosis

Objective

To evaluate the clinical significance of the 2005 modified imaging criteria for dissemination in time in multiple sclerosis stating that detection of a new T2 lesion appearing at any time compared with a reference scan done at least 30 days after the onset of a clinically isolated syndrome implies dissemination in time.

Methods

We included consecutive patients younger than 50 years examined at our center within 3 months of a clinical syndrome suggestive of central nervous system demyelination of the type seen in multiple sclerosis and followed for at least 3 years. We classified patients into one of two groups, according to the timing when reference scan was performed: less than 30 days and at least 30 days after symptom onset. We analyzed the interaction in time to relapse between timing of reference scan and new T2 lesion effect.

Results

A total of 218 patients were included. The hazard ratio (95% confidence interval) of this interaction was 0.90 (0.31–2.62) (or 1.02 (0.27–3.91) in patients with dissemination in space).

Conclusions

We conclude that new T2 lesions increased relapse risk regardless of timing of the reference scan, supporting the use of scans performed at any time within 30 days of symptom onset for dissemination in time demonstration.